HLS Therapeutics (TSE:HLS – Get Free Report) posted its earnings results on Thursday. The company reported C($0.10) EPS for the quarter, FiscalAI reports. The firm had revenue of C$20.15 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%.
Here are the key takeaways from HLS Therapeutics’ conference call:
- Cardiovascular growth lifted Q3 results: Revenue rose 5% year over year to $14.2 million, while Adjusted EBITDA was $5.0 million versus $4.9 million a year earlier. The cardiovascular portfolio grew approximately 21% in local currency and generated $0.7 million in direct brand contribution.
- NILEMDO’s launch is gaining traction: Sales increased 91% sequentially to more than CAD 800,000, with 2,900 patient starts since launch and private coverage now reaching over 80% of privately insured Canadians. HLS expects public-payer negotiations to begin this quarter and, pending approval, plans to launch NEXLIZET in the first half of 2027.
- 2026 Adjusted EBITDA is expected in the lower half of guidance ($18.5 million–$21 million), although revenue is expected near the midpoint of its $56 million–$60 million range. HLS cited additional NILEMDO investment and a faster shift toward cardiovascular products, which currently have lower margins than Clozaril.
- Clozaril results remain mixed: Canadian Q3 sales declined 2.6% in local currency, while U.S. sales were flat year over year and down 6.5% year to date. Management said patient volumes have grown sequentially in recent months, but remain below their 2025 peak.
- HLS added VERQUVO to its cardiovascular portfolio through a capital-efficient Canadian commercialization agreement with Bayer; the company expects modest near-term contribution and estimates peak sales potential of $5 million–$10 million. Management expects growth to step up in 2027 and accelerate in 2028, supported by NILEMDO, potential NEXLIZET approval, and VERQUVO.
HLS Therapeutics Stock Performance
TSE HLS traded down C$0.41 during trading on Thursday, reaching C$3.78. The company’s stock had a trading volume of 55,122 shares, compared to its average volume of 35,888. The firm has a 50 day moving average price of C$4.11 and a 200 day moving average price of C$4.30. HLS Therapeutics has a 12 month low of C$3.56 and a 12 month high of C$5.25. The firm has a market capitalization of C$116.93 million, a price-to-earnings ratio of -14.00 and a beta of -0.52. The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86.
Analyst Ratings Changes
Several research firms recently issued reports on HLS. Canaccord Genuity Group upgraded HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 13th. Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from C$7.00 to C$8.00 in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Strong Buy” and a consensus price target of C$8.00.
Read Our Latest Research Report on HLS Therapeutics
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.
Read More
- Five stocks we like better than HLS Therapeutics
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
